At 1–6 months follow-up, patients with Stage II–III NASH had greater decreases in ALT (−45 ± 18 vs. −10 ± 3, p = 0.02) but not in AST (−19 ± 27 vs. −2 ± 2, p = 0.33) compared with patients with Stage 0−I NASH. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.